The export of ESAT-6 which is a potent T-cell antigen, and related proteins requires a dedicated secretory apparatus that is encoded by a group of genes, several of which also code for proteins that are recognized strongly by T cells. The ESAT-6 systems can consequently be considered as immunogenicity islands and there is mounting evidence that the equivalent genes are subject to selective pressure imposed by the immune system of the host.
This antigen includes many epitopes detectable in the serum of most patients with tuberculosis (more than 90%). By the attempts to obtain the vaccine on the basis of ESAT-6 it was demonstrated that the optimization of adjuvant is very important when using the combination of dioctadecylammonium bromide and monophosphoryllipide.
Recently it was shown that ESAT-6 is very potential as diagnostic for differentiation between the mycobacterial infection and BCG vaccination. The main topic in ESAT-6 using is in antibody production and in test-systems for tuberculosis elaboration.
Patent Protected Countries
The sale and/or commercial use of Recombinant ESAT-6 is prohibited in the United States of America (U.S.A).
ESAT-6 Recombinant produced in Baculovirus is a single, glycosylated, polypeptide chain containing 104 amino acids (1-95 a.a) having a total molecular mass of 11kDa.
The ESAT-6 fused to a 6 amino acid His-tag & purified by proprietary chromatographic techniques.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Avoid multiple freeze-thaw cycles.